-
ONX-0914 (PR-957) for Immune Assays
2026-08-31
ONX-0914 (PR-957) enables selective LMP7-focused experiments that connect cytokine regulation with proteasome-dependent immune signaling. This practical guide covers PBMC assays, autoimmune disease workflows, and a carefully bounded extension into HIV-1 Nef–STAT1 research.
-
Alda 1: ALDH2 Activator for Cardiac Research
2026-08-31
Alda 1 is an ALDH2 activator that increases activity in both ALDH2*1 and the impaired ALDH2*2 variant. Preclinical studies connect ALDH2 activation with aldehyde detoxification, cardioprotection in ischemia, pressure-overload heart-failure delay, and radiation-induced dermatitis mitigation.
-
L-Glutathione Reduced in Translational Redox Research
2026-08-30
L-Glutathione Reduced provides a mechanistically grounded way to interrogate redox buffering, GST activity, and oxidative stress in translational workflows. By connecting reduced glutathione biology with GOT1-driven pancreatic cancer metabolism, this article outlines how researchers can use the reagent as a controlled probe, benchmark, and assay component without confusing redox rescue with therapeutic efficacy.
-
Full-Length αvβ3 Integrin Structures by Cryo-EM
2026-08-29
This study uses extensive cryo-EM analysis to define the conformational diversity of full-length human αvβ3 integrin in apo and ligand-bound states. Its discovery of previously uncharacterized intermediates and distinct CWHM-12-bound states provides a structural framework for understanding integrin activation and designing more selective inhibitors.
-
BIIE 0246: Neuropeptide Y Y2 Receptor Antagonist
2026-08-28
BIIE 0246 is a selective neuropeptide Y Y2 receptor antagonist with nanomolar affinity for Y2R-associated PYY3-36 binding sites. Its validated research uses include NPY Y2 receptor inhibition, presynaptic inhibitory effect blockade, feeding behavior modulation, and investigation of anxiolytic-like behavior.
-
Acifran: A Receptor-Resolved Assay Strategy
2026-08-28
Acifran is a research tool for dissecting HCAR2/GPR109A and HCAR3/GPR109B signaling in lipid metabolism. This article translates recent cryo-EM and cAMP findings into a practical, receptor-resolved framework for assay design, compound handling, and data interpretation.
-
Hexa His Tag Peptide: Cleaner, Smarter Protein IP
2026-08-27
Hexa His tag peptide enables selective competitive elution in antibody-based His-tagged protein workflows. This article connects its assay utility with new CARMIL membrane-binding evidence to improve purification design, interaction analysis, and interpretation of membrane-reconstituted experiments.
-
GSK126 EZH2 Inhibitor: Workflow & Applications
2026-08-27
GSK126 is a selective EZH2 inhibitor for connecting PRC2-driven H3K27me3 loss with gene reactivation, cancer-cell response, and combination-treatment design. This workflow also shows how findings from endothelial dysfunction research can inform, but not replace, oncology-focused validation.
-
Bortezomib (PS-341) Assay Workflows
2026-08-26
Build more informative Bortezomib response experiments by separating growth inhibition from true cell killing. This workflow combines reversible 20S proteasome inhibition with time-resolved viability and apoptosis measurements for stronger interpretation across cancer models.
-
Isoprenaline Hydrochloride in Heart–Brain Models
2026-08-26
Isoprenaline Hydrochloride, also known as isoproterenol, provides a controllable way to activate β1- and β2-adrenergic signaling across cardiac, vascular, respiratory, and neurobehavioral assays. This guide translates published heart–brain findings into practical workflows, controls, and troubleshooting decisions for model development.
-
LLY-507 SMYD2 Inhibitor: Assay Workflows
2026-08-25
LLY-507 combines nanomolar biochemical potency with strong SMYD2 selectivity for target-engagement, cancer-cell, and fibrosis-model workflows. This practical guide connects p53 methylation, proliferation, apoptosis, and renal-fibrosis readouts while emphasizing formulation control and preclinical limitations.
-
Trametinib for MEK-ERK Assay Design
2026-08-25
Trametinib (GSK1120212) turns MEK1/2 inhibition into a practical readout strategy for cancer, pathway, and neuronal signaling experiments. This guide connects dose planning, pERK validation, G1 arrest and apoptosis assays with a recent DRG-neuron study that clarifies how oxidative signaling can activate the B-Raf–MEK–ERK axis.
-
Fasudil (HA-1077) HCl: ROCK Assay Workflows
2026-08-24
Build reproducible ROCK signaling experiments with Fasudil (HA-1077) HCl across migration, proliferation, and apoptosis models. This guide pairs practical dosing and readout strategies with a cautious framework for testing Rho/ROCK–Hippo pathway relationships without overinterpreting cross-domain evidence.
-
U-73122 for Reliable PLC Signaling Assays
2026-08-24
A scenario-based guide to using U-73122 (SKU B3422) in calcium flux, chemotaxis, viability, proliferation, and inflammation workflows. It explains dose interpretation, solvent control, assay compatibility, evidence limits, and practical criteria for selecting a reliable phospholipase C inhibitor.
-
Annexin V-PE Reagent for Apoptosis Assays
2026-08-23
Annexin V-PE Reagent is an Annexin V fluorescent conjugate for rapid phosphatidylserine externalization detection. Its 15–30-minute staining workflow supports fluorescence microscopy and flow cytometry, including apoptosis analysis in CAR-T research.